Clinical trial · Interventional
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma
NCT00190424CI-TRIAL-00008670completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CpG-ODN | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- control
- type
- EXPERIMENTAL
- label
- CpG-ODN
- interventionNames
- Drug: CpG-ODN
Primary outcomes (1)
- measure
- Survival
- timeFrame
- 2 years
Secondary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- 2 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Glioblastoma * Karnofsky Performance Status ≥ 60% Exclusion Criteria: * Severe or uncontrolled systemic disease * Active auto-immune disease * Uncontrolled epilepsia * Platelets \< 100 000/mm3 ; or Neutrophils \<500 /mm3 ; or lymphocytes \<300/ mm3
References
Publications (0)
Data not yet available
No reference posted for this study.